P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
- Resource Type
- article
- Source
- HemaSphere, Vol 7, p e44640da (2023)
- Subject
Diseases of the blood and blood-forming organs RC633-647.5 - Language
- English
- ISSN
- 2572-9241